Martine Zimmermann - 08 Sep 2026 Form 4 Insider Report for Candel Therapeutics, Inc. (CADL)

Reporting relationship: Director
Issuer ticker: CADL
Reported as of: 08 Sep 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 10 Sep 2026, 16:24:20 UTC
Prior SEC filing: 09 Jun 2026
Next SEC filing: 14 Sep 2026
Source filing: View source filing
Reporting owner signature: /s/ Charles Schoch, as Attorney-In-Fact for Martine Zimmermann

Key filing fact

Martine Zimmermann filed Form 4 for Candel Therapeutics, Inc. (CADL) on 10 Sep 2026.

Key facts

This page summarizes Martine Zimmermann's Form 4 filing for Candel Therapeutics, Inc. (CADL).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 10 Sep 2026, 16:24.

Change

Previous filing in this sequence was filed on 09 Jun 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001994049 Primary reporting owner

Zimmermann Martine

Relationship: Director
Address: C/O CANDEL THERAPEUTICS, INC., 117 KENDRICK ST., SUITE 450, NEEDHAM
Signature: /s/ Charles Schoch, as Attorney-In-Fact for Martine Zimmermann
Signature date: 10 Sep 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CADL transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +64,000
Change %
Price: $0.000000^*
Shares after: 64,000
Date: 08 Sep 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 64,000
Exercise price: $12.60
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The shares underlying this option shall vest and become exercisable in thirty-six (36) equal monthly installments, subject to the Reporting Person's continued service on each such vesting date.